1
|
Huang M, Wang W, Wang Y, Wang R, Pan L, Li X, Li B, Zhang J, Wang R, Zhang Y, Tian R. Advancing cancer therapy with a heptamethine carbocyanine dye-conjugated radionuclide drug. J Mater Chem B 2024; 13:256-263. [PMID: 39530533 DOI: 10.1039/d4tb01798f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2024]
Abstract
Malignant tumors pose substantial treatment challenges due to their heterogeneity, metastatic potential, and therapeutic resistance, underscoring the urgent need for more effective treatment options. In this study, a novel radionuclide drug conjugate (RDC) was developed and characterized employing a tumor-targeting heptamethine carbocyanine dye (DZ) for its high specificity and favourable safety profile. The RDC, DOTA-DZ-HX, was synthesized by conjugating DZ with dodecane tetraacetic acid (DOTA) through a dipeptide linker. The anti-tumor efficacy and biodistribution of [177Lu]Lu-DOTA-DZ-HX were assessed in H1975 and HeLa xenograft models. [177Lu]Lu-DOTA-DZ-HX showed high stability, specific tumor accumulation, and substantial radioactivity retention at the tumor site for seven days. Biodistribution analysis revealed that the drug exhibited prolonged blood circulation with gradual clearance. Additionally, [177Lu]Lu-DOTA-DZ-HX could effectively and selectively inhibit tumor growth, as evidenced by a significant reduction in tumor volume. These findings suggest that heptamethine carbocyanine dye-directed radionuclide targeting could provide an effective treatment for cancer and potentially other malignancies, representing a significant advancement in cancer therapy.
Collapse
Affiliation(s)
- Mingxing Huang
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
| | - Weichen Wang
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
| | - Yingwei Wang
- Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, China
| | - Rang Wang
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
| | - Lili Pan
- Department of Nuclear Medicine and Clinical Nuclear Medicine Research Lab, West China Hospital, Sichuan University, Chengdu, China
| | - Xin Li
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
| | - Bo Li
- Nuclear Power Institute of China, National Engineering Research Center of Isotope and Medicine, and Radioisotope Engineering Technology Research Center of Sichuan, Chengdu, China
| | - Jingsong Zhang
- Nuclear Power Institute of China, National Engineering Research Center of Isotope and Medicine, and Radioisotope Engineering Technology Research Center of Sichuan, Chengdu, China
| | - Ruoxiang Wang
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
| | - Yi Zhang
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
| | - Rong Tian
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
| |
Collapse
|
2
|
Wang B, Lu Z, Song M, He X, Hu Z, Liang H, Lu H, Chen Q, Liang B, Yi T, Wei P, Jiang L, Dong J. Single-Component Dual-Functional Autoboost Strategy by Dual Photodynamic and Cyclooxygenase-2 Inhibition for Lung Cancer and Spinal Metastasis. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2024; 11:e2303981. [PMID: 38224203 PMCID: PMC10966547 DOI: 10.1002/advs.202303981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/17/2023] [Revised: 12/24/2023] [Indexed: 01/16/2024]
Abstract
Coloading adjuvant drugs or biomacromolecules with photosensitizers into nanoparticles to enhance the efficiency of photodynamic therapy (PDT) is a common strategy. However, it is difficult to load positively charged photosensitizers and negatively charged adjuvants into the same nanomaterial and further regulate drug release simultaneously. Herein, a single-component dual-functional prodrug strategy is reported for tumor treatment specifically activated by tumor microenvironment (TME)-generated HOCl. A representative prodrug (DHU-CBA2) is constructed using indomethacin grafted with methylene blue (MB). DHU-CBA2 exhibited high sensitivity toward HOCl and achieved simultaneous release of dual drugs in vitro and in vivo. DHU-CBA2 shows effective antitumor activity against lung cancer and spinal metastases via PDT and cyclooxygenase-2 (COX-2) inhibition. Mechanistically, PDT induces immunogenic cell death but stimulates the gene encoding COX-2. Downstream prostaglandins E2 and Indoleamine 2,3 dioxygenase 1 (IDO1) mediate immune escape in the TME, which is rescued by the simultaneous release of indomethacin. DHU-CBA2 promotes infiltration and function of CD8+ T cells, thus inducing a robust antitumor immune response. This work provides an autoboost strategy for a single-component dual-functional prodrug activated by TME-specific HOCl, thereby achieving favorable tumor treatment via the synergistic therapy of PDT and a COX-2 inhibitor.
Collapse
Affiliation(s)
- Ben Wang
- Department of Orthopaedic SurgeryZhongshan HospitalFudan UniversityShanghai200032China
| | - Zhen‐Ni Lu
- State Key Laboratory for Modification of Chemical Fibers and Polymer MaterialsCollege of Chemistry and Chemical EngineeringDonghua UniversityShanghai201620China
| | - Meng‐Xiong Song
- Department of Orthopedics SurgeryMinhang HospitalFudan UniversityShanghai201100China
| | - Xiao‐Wen He
- Department of Orthopaedic SurgeryShanghai Baoshan District Wusong Center HospitalFudan UniversityShanghai200940China
| | - Zhi‐Chao Hu
- Department of Orthopaedic SurgeryZhongshan HospitalFudan UniversityShanghai200032China
| | - Hai‐Feng Liang
- Department of Orthopaedic SurgeryZhongshan HospitalFudan UniversityShanghai200032China
| | - Hong‐Wei Lu
- Department of Orthopaedic SurgeryZhongshan HospitalFudan UniversityShanghai200032China
| | - Qing Chen
- Department of Orthopaedic SurgeryZhongshan HospitalFudan UniversityShanghai200032China
| | - Bing Liang
- Department of Orthopaedic SurgeryZhongshan HospitalFudan UniversityShanghai200032China
| | - Tao Yi
- State Key Laboratory for Modification of Chemical Fibers and Polymer MaterialsCollege of Chemistry and Chemical EngineeringDonghua UniversityShanghai201620China
| | - Peng Wei
- State Key Laboratory for Modification of Chemical Fibers and Polymer MaterialsCollege of Chemistry and Chemical EngineeringDonghua UniversityShanghai201620China
| | - Li‐Bo Jiang
- Department of Orthopaedic SurgeryZhongshan HospitalFudan UniversityShanghai200032China
| | - Jian Dong
- Department of Orthopaedic SurgeryZhongshan HospitalFudan UniversityShanghai200032China
- Department of Orthopaedic SurgeryShanghai Baoshan District Wusong Center HospitalFudan UniversityShanghai200940China
| |
Collapse
|